Clinical trials: Recurrent Tumor
Otitis Media With Effusion in Children, Otitis Media Recurrent
Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT)
The purpose of this study is to evaluate EXE844 plus tympanostomy tubes compared to tympanostomy tubes only based on sustained clinical cure at end-of-therapy (EOT).
- Trial name
- NCT02432105
- Testing
- EXE844 Sterile Otic Suspension, 0.3%, Tympanostomy Tube Insertion
- Volunteers
- 470 people
- Sponsor
- Alcon Research
Pancreatic Cancer
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Determining the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of advanced or metastatic pancreatic cancer.
- Trial name
- NCT02117479
- Testing
- Ruxolitinib, Capecitabine
- Where
- 230 sites in United States, Australia and 10 more
- Volunteers
- 321 people
- Sponsor
- Incyte Corporation
NSCLC
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in combination with PDCT in the first-line treatment of…
- Trial name
- NCT06094296
- Testing
- BMS-986315, Nivolumab, Pemetrexed
- Where
- 8 sites in United States, Australia
- Volunteers
- 1 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukaemia Recurrent
The Effects of AMPC in the Treatments of Refractory or Relapsed AML
A private trial for evaluating the overall response rate contributed by AMPC in AML in refractory or relapsed AML
- Trial name
- AMPCAL (NCT03825146)
- Testing
- Autologous Multi-lineage Potential Cells (AMPC)
- Where
- Thailand
- Volunteers
- 10 people
- Sponsor
- Lai Corporation Pty. Ltd.
Head and Neck Squamous Cell Carcinoma
Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients
To establish whether LJM716 in combination with cetuximab is safe and has beneficial effects in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT02143622
- Testing
- LJM716, cetuximab
- Sponsor
- Novartis Pharmaceuticals
Recurrent Platinum-sensitive Ovarian Cancer
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.
- Trial name
- NCT01837251
- Testing
- Carboplatin, PLD, Bevacizumab
- Where
- 193 sites in Australia, Austria and 4 more
- Volunteers
- 682 people
- Sponsor
- AGO Research GmbH
Head and Neck Cancer
A Study in Head and Neck Cancer
This study will begin with a 30 participant lead-in part: these 30 participants will receive cetuximab manufactured by ImClone on a weekly basis in combination with other chemotherapy drugs [cisplatin or carboplatin plus…
- Trial name
- NCT01081041
- Testing
- Cetuximab, Cisplatin, Carboplatin
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1…
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT05605522
- Testing
- [225]-FPI-2059, [111In]-FPI-2058
- Where
- 8 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- 3B Pharmaceuticals GmbH
Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 in combination with cytarabine in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid…
- Trial name
- NCT05241093
- Testing
- HYML-122; cytarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tarapeutics Science Inc.
Brain Tumors
Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Bradmer Pharmaceuticals, Inc. (Bradmer) is requesting approval to study the safety of Neuradiab® when combined with Bevacizumab (Avastin) therapy given at a minimum of 30 days after Neuradiab administration in patients with a…
- Trial name
- NCT00906516
- Testing
- Neuradiab in combination with Bevacizumab (Avastin)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Bradmer Pharmaceuticals Inc.
Breast Cancer
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast…
- Trial name
- NCT01077154
- Testing
- Denosumab
- Where
- 459 sites in United States, Argentina and 37 more
- Volunteers
- 4,509 people
- Sponsor
- Amgen
Breast Cancer
A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
This phase II study is a clinical study to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with unresectable locally advanced or recurrent metastatic HER-2 negative…
- Trial name
- NCT06042894
- Testing
- BL-B01D1, SI-B003
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non-Small-Cell Lung Carcinoma
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR…
- Trial name
- CheckMate722 (NCT02864251)
- Testing
- Nivolumab, Ipilimumab, Pemetrexed
- Where
- 109 sites in United States, Canada and 8 more
- Volunteers
- 367 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
The study consists of three parts: Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple…
- Trial name
- DynaMMic-1 (NCT05714839)
- Testing
- Belantamab, Belantamab mafodotin, Pomalidomide
- Where
- 44 sites in United States, Argentina and 11 more
- Volunteers
- 123 people
- Sponsor
- GlaxoSmithKline
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent
- Trial name
- NCT05645744
- Testing
- Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product.
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mustang Bio
Glioblastoma, Astrocytoma, Grade IV
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM
The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies.
- Trial name
- CerebralEDV (NCT02766699)
- Testing
- EGFR(V)-EDV-Dox
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Engeneic Pty Limited
Breast Cancer, Hormone Receptor Positive Tumor
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
The purpose of this study is to evaluate the efficacy and quality of life in women with advanced breast cancer (locally advance inoperable or metastatic adenocarcinoma of the breast), HR+ / HER2-, who are treated with an…
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- INGE-B (NCT02894398)
- Testing
- Palbociclib, Letrozole, Anastrozole
- Where
- 70 sites in Germany
- Volunteers
- 388 people
- Sponsor
- iOMEDICO AG
Glioblastoma
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive…
- Trial name
- NCT06061809
- Testing
- Bevacizumab, PD-L1 t-haNK, N-803
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- ImmunityBio, Inc.
Gynecological Tumors
A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of…
- Trial name
- NCT06798207
- Testing
- TQB2102 for injection
- Where
- 31 sites in China
- Volunteers
- 170 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Carcinoma
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
The goal of this clinical trial is to understand the effectiveness of dostarlimab and carboplatin-paclitaxel followed by dostarlimab monotherapy in participants with endometrial cancer
- Trial name
- RUBY-J (NCT06317311)
- Testing
- Dostarlimab, Carboplatin, Paclitaxel
- Where
- 15 sites in Japan
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.